Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Insilico Sells Global Rights for KAT6A Inhibitor to Menarini in $500 Million Deal

publication date: Jan 9, 2024

Hong Kong’s Insilico Medicine sold global rights for its small molecule KAT6A inhibitor to Stemline Therapeutics, an oncology subsidiary of Italy’s Menarini Group, in a $500 million ($12 million upfront) agreement. Insilico, an AI drug discovery company, said the candidate targets hormone sensitive cancers and other oncology indications. Overexpression of KAT6A is associated with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of the disease. In preclinical studies, the candidate showed inhibition against KAT6A in multiple CDX and PDX models with good efficacy and safety. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital